Biologicals Continue to Change the Therapeutic Picture for Autoimmunity

Greystone Associates Analyzes the Evolving Treatment Landscape as Increasing Numbers of Biological Drugs Targeting Autoimmune Diseases Reach the Market

[USPRwire, Thu Apr 29 2010] So-called biological drugs – mammalian biochemicals that have proven therapeutic value and are manufactured in host systems under strict conditions – continue to generate high levels of investment and competitive interest as companies pursue treatments for a number of historically refractory conditions. These powerful drugs have brought significant change to the treatment strategies for several major disease segments. The treatment protocols for a number of important cancers now include one or more monoclonal antibodies. But it is patients afflicted with autoimmune diseases that have experienced the most benefit from biologicals, as drugs such as Enbrel, Humira, Simponi, and Cimzia become the cornerstone of treatment for a growing number of patients with advanced forms of autoimmunity.

In spite of recent progress, a number of autoimmune diseases continue to represent an area of significant unmet need. Recognizing the market potential, drug developers are currently sponsoring more than fifty clinical trials that are aimed at autoimmune diseases. More than two dozen biological pipeline candidates targeting various forms of autoimmunity are in mid-to-late stage clinical development.

A new research study - Autoimmune Markets for therapeutic Biologicals - analyzes the treatment landscape for a number of key autoimmune disorders, a landscape that continues to evolve as new treatments enter the market. The study examines the impact of these new biologicals on established recombinant drugs such as the TNF inhibitors that have already attained an annual ex-manufacturer market value of more than $13 billion for inflammatory types of autoimmunity alone. It also identifies the key players in each therapeutic segment, describes the regulatory and commercial environment, and assesses the dynamics of patient care that will affect market development. The report includes forecasts to 2013.

More information is available at www.greystoneassociates.org .

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Contact:

Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org

Source: Greystone Associates